Transgene SA
TRGNF
$0.70
-$0.89-55.98%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 15.10K | 15.20K | 629.20K |
| Total Other Revenue | 1.81M | 1.82M | 1.67M | 1.69M | 2.59M |
| Total Revenue | 1.81M | 1.82M | 1.69M | 1.71M | 2.59M |
| Cost of Revenue | 8.30M | 8.37M | 7.55M | 7.63M | 8.47M |
| Gross Profit | -6.49M | -6.55M | -5.86M | -5.92M | -5.88M |
| SG&A Expenses | 2.45M | 2.47M | 2.01M | 2.03M | 1.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -69.40K | -70.00K | 32.80K | 33.20K | 694.50K |
| Total Operating Expenses | 10.68M | 10.78M | 9.59M | 9.70M | 10.94M |
| Operating Income | -8.88M | -8.95M | -7.90M | -7.99M | -8.35M |
| Income Before Tax | -8.87M | -8.95M | -3.46M | -3.50M | -8.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.87M | -8.95M | -3.46M | -3.50M | -8.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.87M | -8.95M | -3.46M | -3.50M | -8.65M |
| EBIT | -8.88M | -8.95M | -7.90M | -7.99M | -8.35M |
| EBITDA | -8.68M | -8.76M | -7.25M | -7.33M | -7.91M |
| EPS Basic | -0.09 | -0.09 | -0.03 | -0.03 | -0.09 |
| Normalized Basic EPS | -0.05 | -0.06 | -0.02 | -0.02 | -0.05 |
| EPS Diluted | -0.09 | -0.09 | -0.03 | -0.03 | -0.09 |
| Normalized Diluted EPS | -0.05 | -0.06 | -0.02 | -0.02 | -0.05 |
| Average Basic Shares Outstanding | 100.96M | 100.96M | 101.38M | 101.38M | 99.80M |
| Average Diluted Shares Outstanding | 100.96M | 100.96M | 101.38M | 101.38M | 99.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
